The Chronic Lymphocytic Leukemia Channel is supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ICML 2019 | Venetoclax: undetectable peripheral blood MRD status as a therapeutic goal in R/R CLL
Sasanka Handunnetti, MBBS, Peter MacCallum Cancer Centre, Melbourne, Australia, discusses the use of an undetectable peripheral blood MRD status as a therapeutic goal in patients with relapsed/refractory chronic lymphocytic leukemia (CLL) treated with venetoclax in a retrospective analysis. This interview took place at the 15th International Conference on Malignant Lymphoma (ICML), in Lugano, Switzerland.
